Trial Profile
A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel rechallenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with docetaxel at inception of primary hormone therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms CANTATA
- 04 Sep 2015 Accrual to date is 10% according to the United Kingdom Clinical Research Network record.
- 12 Aug 2015 Accrual to date is 9% according to United Kingdom Clinical Research Network record.
- 02 Jul 2015 Accrual to date is 8% according to United Kingdom Clinical Research Network record.